This content is intended for the general public

R&D PIPELINE


Blue Earth Diagnostics’ commitment is to develop and commercialise innovative radiopharmaceutical agents that have the potential to inform management decisions for patients with serious disease, such as cancer. These agents are designed to have a positive impact on patient care, with a focus on areas of significant unmet medical need. Here you can explore details of our research pipeline, arranged by product.

These products are undergoing clinical trials in the therapeutic areas listed and are not yet licensed.


Product/Candidate
DISEASE/THERAPEUTIC AREA
Application
Preclinical
Phase 1
Phase 2
Phase 3

fluciclovine(18F)

Brain metastases

PET imaging

FAP-targeted technology

Multiple solid tumours 

PET imaging
pipeline-1

Our sister company, Blue Earth Therapeutics, continues to investigate the use of radiopharmaceuticals in the therapy setting. For more information see:

https://www.blueearththerapeutics.com/pipeline

 

UKBED-N/A-2500024 April 2025